Clinical Trials
13 trialsNCT05415215 2026-02-10
ProHer
Hoffmann-La Roche
Phase 3 Completed
NCT03725059 2025-07-11
KEYNOTE-756
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT04109066 2025-01-08
CheckMate 7FL
Bristol-Myers Squibb
Phase 3 Completed
NCT03493854 2024-06-26
FeDeriCa
Hoffmann-La Roche
Phase 3 Completed
NCT04629846 2024-04-19
Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel.
Qilu Pharmaceutical Co., Ltd.
Phase 3 Completed
NCT03272477 2024-04-17
TP-II
Palleos Healthcare GmbH
Phase 2 Completed
NCT02586025 2023-05-22
PEONY
Hoffmann-La Roche
Phase 3 Completed
NCT03916744 2023-03-10
A Study of Giredestrant (GDC-9545) in Postmenopausal Women With Stage I-III Operable, Estrogen Receptor-Positive Breast Cancer
Genentech, Inc.
Phase 1 Completed
NCT04436744 2023-02-02
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer)
Hoffmann-La Roche
Phase 2 Completed
NCT01142778 2018-03-16
AVATAXHER
Hoffmann-La Roche
Phase 2 Completed
NCT00849472 2014-03-04
Treatment With Pazopanib for Neoadjuvant Breast Cancer
GlaxoSmithKline
Phase 2 Completed
NCT00191789 2010-07-27
Neoadjuvant Sequential Administration of Two Gemcitabine Combinations in Operable Breast Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00161980 2006-10-23
Efficacy and Safety of Fibrin Sealant Vapor Heated Solvent/Detergent Treated (FS VH S/D) for Reduction of Lymphatic Leakage by Sealing Axillary Lymph Node Dissection Sites
Baxter Healthcare Corporation
Phase 3 Completed